Search PubMed⌕ Search

PubMed · 577451

[Therapy with coronary dilators].

Abstract

The pathophysiological basis of antianginal therapy with vasodilating agents is critically reviewed. The concept of specific coronary vasodilation should not be pursued in the search for new antianginal agents. Although controlled clinical trials with coronary vasodilators in patients have been successful, no inferences can be drawn as to the concept of coronary vasodilation since most of these compounds vasodilate only the coronaires of experimental animals after i.v. administration but not those of humans after oral ingestion. The stimulating influence of coronary vasodilators on coronary collaterals is an interesting but so far unproven claim. Nitroglycerine dilates the large epicardial coronary vessels. This effect can be of significance in excentric stenoses where the arterial wall is to a small part intact.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W Schaper. 1977. [Therapy with coronary dilators].. https://pubmed.ncbi.nlm.nih.gov/577451/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗